Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-09-13

Clinical Trial Update: Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating sunitinib in patients with Von Hippel-Lindau disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sutent (sunitinib)

Snippet

Sponsor: Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | Conditions: Von Hippel-Lindau Disease | Phase 2 | Status: COMPLETED